Lab21 has expanded its range of diagnostic and blood-banking products with the launch of a CE-marked enzyme immunoassay for the detection of cytomegalovirus (CMV) antibodies in human serum or plasma.
The company has developed an immunodiagnostic assay for total CMV antibody detection that is claimed to be more sensitive than other commercially available CMV assays.
This sensitivity means that the Lab21 system can detect a potential CMV infection earlier than previously and so give additional assurance that a blood sample is uninfected, minimising the risk of blood-borne transmission.
